Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2013-10-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protective Effects of Normobaric Hyperoxia on Blood Brain Barrier in Patients With Acute Ischemic Stroke
NCT02974283
Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke
NCT06170086
Deproteinised Calf Blood Serum Injection for the Treatment of Acute Intracerebral Hemorrhage
NCT03260153
Monitoring of the Ischemic Stroke Patient Through the Use of New Serum Biomarkers and MRI Imaging
NCT05812846
Adjuvant Cerebroprotection Using Normobaric Hyperoxia in Pre-hospital Patients with Suspected Stroke
NCT06801457
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute ischemic stroke
Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admission within 12 hours
Exclusion Criteria
* Cerebral hemorrhagic infarction
* Epilepsy or epileptic persons
* History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases
* Contraindications to antiplatelet treatments
* Serial blood samples could not be obtained
42 Years
76 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 6th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hao Chen
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lixia Xue, M.D., Ph.D.
Role: STUDY_DIRECTOR
Shanghai 6th People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Sixth People's Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H1583-660145
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.